CLINICAL_TRIALS
withdrawal
· 2021-11-26
Clinical Trial Update: Open-label Extension Study for CLCZ696G2301 (PARADISE-MI) [Phase 3]
Summary
Open-label extension study for CLCZ696G2301 (PARADISE-MI) has been withdrawn, affecting post-myocardial infarction population.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Post Myocardial Infarction | Phase 3 | Status: WITHDRAWN